CytoTronics Revenue and Competitors

Boston, MA USA

Location

$23M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CytoTronics's estimated annual revenue is currently $2.9M per year.(i)
  • CytoTronics's estimated revenue per employee is $77,500
  • CytoTronics's total funding is $23M.

Employee Data

  • CytoTronics has 37 Employees.(i)
  • CytoTronics grew their employee count by 37% last year.

CytoTronics's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Co-founder & CBOReveal Email/Phone
3
Co-founder & CTOReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Head Biology and Data ScienceReveal Email/Phone
6
Executive ChairmanReveal Email/Phone
7
Principal ScientistReveal Email/Phone
8
Principal Software EngineerReveal Email/Phone
9
Principal ASIC Design EngineerReveal Email/Phone
10
Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is CytoTronics?

CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Building upon a suite of innovations licensed from Harvard University, CytoTronics’s technology measures and manipulates live cells to produce real-time, high resolution electrical and electrochemical cell-based assays. By providing unique single-cell resolution readouts that are not currently available in today’s cell-based drug screening market, CytoTronics is enhancing the accuracy of cell-biology information that can be used to revolutionize drug discovery.

keywords:N/A

$23M

Total Funding

37

Number of Employees

$2.9M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.1M3712%N/A
#2
$696.5M370%N/A
#3
$9.6M37-18%N/A
#4
$6.2M37-3%N/A
#5
$6.2M373%N/A